Funding, M&A, exec moves and hiring — every signal, the moment it breaks.See plans →
Opal Therapeutics secures a $1.25M investment to enhance its laboratory infrastructure and patient-derived organoid manufacturing.
PRIVATEAug 07, 2026•2 days ago
Amount Raised
$1.25 Million
Round Type
Seed
San FranciscoBiotechnologyHealth CareTherapeutics
Investors
National Science Foundation
Description
Opal Therapeutics, based in San Francisco, CA, has received a $1.25M investment from the National Science Foundation. The funds will be used to scale laboratory infrastructure and expand internal datasets. The company focuses on therapeutic development in women's gynecological health. They utilize a platform that isolates cells from menstrual blood to create organoid models for disease research.
Company Information
Company
Opal Therapeutics
Location
San Francisco, California, United States
About
Opal Therapeutics is a biotechnology company focused on enabling treatments and diagnostics for chronic diseases in women’s reproductive health, including endometriosis, fibroids, PCOS, and heavy menstrual bleeding. Their platform isolates cells from menstrual blood and surgical biopsies to establish a biobank of organoid and cellular models that capture disease signatures of respective patients. They aim to provide deeper in vitro and in silico insights by pairing patient tissue data with computational analysis. Opal Therapeutics serves the pharmaceutical and biotech industries to de-risk early pre-clinical discovery.
Related People
Suggested for you
1 contact
Verified contactsMorgan, Chief Executive Officer
Predictive Intelligence
Strategic
ML-powered predictions for Opal Therapeutics's next move
San FranciscoBiotechnologyHealth CareTherapeutics